Printer Friendly

Canopy Growth agrees to acquire Beckley Canopy Therapeutics.

BANKING AND CREDIT NEWS-August 14, 2019-Canopy Growth agrees to acquire Beckley Canopy Therapeutics

(C)2019 M2 COMMUNICATIONS http://www.m2.com

Canopy Growth Corporation (TSX: WEED), (NYSE: CGC) has announced that it has entered into an agreement to acquire the global cannabinoid-based medical researcher Beckley Canopy Therapeutics, the company said.

The acquisition brings together Canopy's wholly owned research program with the Beckley Canopy research platform which is partly owned by Canopy Growth in order to combine the best teams, programs and clinical work all under a single strategic plan. The research arm in turn directly supports the commercial efforts of Spectrum Therapeutics around the world. As part of the acquisition, Canopy Growth also acquires the outstanding shares in Spectrum Biomedical UK, the commercial arm of the company in the United Kingdom, as that markets begins to develop into a commercially viable opportunity.

With the acquisition of C3, and Canopy Growth's expanding research and development plans worldwide, the company is solidifying its status as a truly global provider of cannabinoid research. Spectrum Therapeutics will leverage Beckley Canopy's intellectual property, accelerate its comprehensive research programs, build evidence around the company's products and formulations and ultimately improve patient access to cannabinoid-based medicines globally.

Beckley Canopy was formed as a joint venture in January 2018 between Beckley Research & Innovations ("BRI") and Canopy Growth to research and develop clinically validated cannabis-based medicines, with a strong focus on intellectual property protection. The research platform combined European and North American-based leaders in cannabis research from BRI and Canopy Growth to create a strong and complementary UK-based European partnership.

Since its inception, Beckley Canopy has made significant progress in three initial areas of research, namely cancer pain, opioid sparing, and smoking cessation, with further research in progress.

Once the acquisition is complete, Beckley Canopy will be fully integrated into the current Spectrum Therapeutics platform and management team in Europe, a region of focus for the company as policy surrounding medical cannabis and patient access continues to evolve. The leadership team at Beckley Canopy has demonstrated a strong track record of success in the short period since its inception, and the senior research team boasts a combined 75 years of pharmaceutical research globally.

The acquisition remains subject to certain regulatory approvals and closing conditions, and if satisfied, is expected to close within the next 60 days.

Canopy Growth is a world-leading diversified cannabis, hemp and cannabis device company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms, as well as medical devices through Canopy Growth's subsidiary, Storz & Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. Canopy Growth has operations in over a dozen countries across five continents.

Canopy Growth's medical division, Spectrum Therapeutics is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public's understanding of cannabis, and has devoted millions of dollars toward cutting edge, commercializable research and IP development. Spectrum Therapeutics sells a range of full-spectrum products using its colour-coded classification Spectrum system as well as single cannabinoid Dronabinol under the brand Bionorica Ethics. For more information visit www.canopygrowth.com

((Comments on this story may be sent to info@m2.com))
COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Banking & Credit News (BCN)
Date:Aug 14, 2019
Words:554
Previous Article:Torchmark officially renamed Globe Life Inc.
Next Article:BitKan, Bitcoin.com plan strategic partnership.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |